Logo image of SVRA

SAVARA INC (SVRA) Stock Fundamental Analysis

NASDAQ:SVRA - Nasdaq - US8051111016 - Common Stock - Currency: USD

2.69  0 (0%)

After market: 2.68 -0.01 (-0.37%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SVRA. SVRA was compared to 571 industry peers in the Biotechnology industry. The financial health of SVRA is average, but there are quite some concerns on its profitability. SVRA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SVRA has reported negative net income.
SVRA had a negative operating cash flow in the past year.
SVRA had negative earnings in each of the past 5 years.
In the past 5 years SVRA always reported negative operating cash flow.
SVRA Yearly Net Income VS EBIT VS OCF VS FCFSVRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

SVRA's Return On Assets of -34.73% is fine compared to the rest of the industry. SVRA outperforms 62.52% of its industry peers.
Looking at the Return On Equity, with a value of -41.60%, SVRA is in the better half of the industry, outperforming 71.05% of the companies in the same industry.
Industry RankSector Rank
ROA -34.73%
ROE -41.6%
ROIC N/A
ROA(3y)-27.48%
ROA(5y)-38.13%
ROE(3y)-34.71%
ROE(5y)-51.61%
ROIC(3y)N/A
ROIC(5y)N/A
SVRA Yearly ROA, ROE, ROICSVRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SVRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SVRA Yearly Profit, Operating, Gross MarginsSVRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, SVRA has more shares outstanding
Compared to 5 years ago, SVRA has more shares outstanding
Compared to 1 year ago, SVRA has an improved debt to assets ratio.
SVRA Yearly Shares OutstandingSVRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
SVRA Yearly Total Debt VS Total AssetsSVRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

An Altman-Z score of 4.15 indicates that SVRA is not in any danger for bankruptcy at the moment.
SVRA has a better Altman-Z score (4.15) than 78.69% of its industry peers.
SVRA has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
SVRA's Debt to Equity ratio of 0.13 is on the low side compared to the rest of the industry. SVRA is outperformed by 67.85% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z 4.15
ROIC/WACCN/A
WACCN/A
SVRA Yearly LT Debt VS Equity VS FCFSVRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 17.70 indicates that SVRA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 17.70, SVRA belongs to the top of the industry, outperforming 92.36% of the companies in the same industry.
A Quick Ratio of 17.70 indicates that SVRA has no problem at all paying its short term obligations.
SVRA has a Quick ratio of 17.70. This is amongst the best in the industry. SVRA outperforms 92.36% of its industry peers.
Industry RankSector Rank
Current Ratio 17.7
Quick Ratio 17.7
SVRA Yearly Current Assets VS Current LiabilitesSVRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

SVRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.71%.
EPS 1Y (TTM)-38.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 22.81% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-47.82%
EPS Next 2Y-20.38%
EPS Next 3Y2.04%
EPS Next 5Y22.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SVRA Yearly Revenue VS EstimatesSVRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
SVRA Yearly EPS VS EstimatesSVRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SVRA. In the last year negative earnings were reported.
Also next year SVRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SVRA Price Earnings VS Forward Price EarningsSVRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SVRA Per share dataSVRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.38%
EPS Next 3Y2.04%

More info and screens

0

5. Dividend

5.1 Amount

SVRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAVARA INC

NASDAQ:SVRA (2/21/2025, 8:00:01 PM)

After market: 2.68 -0.01 (-0.37%)

2.69

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-13 2025-03-13/amc
Inst Owners91.02%
Inst Owner Change-98.91%
Ins Owners2.32%
Ins Owner Change2.63%
Market Cap461.66M
Analysts84.29
Price Target9.75 (262.45%)
Short Float %9.87%
Short Ratio14.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.08%
Min EPS beat(2)-8.6%
Max EPS beat(2)0.45%
EPS beat(4)2
Avg EPS beat(4)-1.16%
Min EPS beat(4)-11.37%
Max EPS beat(4)14.89%
EPS beat(8)5
Avg EPS beat(8)-2.76%
EPS beat(12)7
Avg EPS beat(12)0.93%
EPS beat(16)9
Avg EPS beat(16)-6.83%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.34%
EPS NQ rev (1m)-1.21%
EPS NQ rev (3m)-17.6%
EPS NY rev (1m)-4.5%
EPS NY rev (3m)-7.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.32
P/tB 2.45
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0
BVpS1.16
TBVpS1.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.73%
ROE -41.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.48%
ROA(5y)-38.13%
ROE(3y)-34.71%
ROE(5y)-51.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 47.2%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.7
Quick Ratio 17.7
Altman-Z 4.15
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)153.1%
Cap/Depr(5y)347.91%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
EPS Next Y-47.82%
EPS Next 2Y-20.38%
EPS Next 3Y2.04%
EPS Next 5Y22.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-68.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.99%
EBIT Next 3Y27.97%
EBIT Next 5YN/A
FCF growth 1Y-130.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-130.88%
OCF growth 3YN/A
OCF growth 5YN/A